Common Stock, $0.001 par value per share
- Symbol
- NPCE
- Exchange
- NASDAQ
- Classification
- COMMON
- Status
- Current
Current Report · Items 2.02, 9.01 · 8-K
NPCENASDAQEQUITYCurrent
Item 2.02 Results of Operations and Financial Condition. On November 12, 2026, the Company issued a press release announcing its financial results for the fiscal quarter ended September 30, 2026. A copy of the press release, dated November 12, 2026, is furnished hereto as Exhibit 99.1 and is incorporated herein by reference.…
Press release in this filing
NeuroPace Reports Third Quarter 2026 Financial Results and Provides Revised Full Year Guidance →Based in Mountain View, Calif., NeuroPace is a medical device company focused on transforming the lives of people living with epilepsy by reducing or eliminating the occurrence of debilitating seizures. Its novel and differentiated RNS System is the first and only commercially available, brain-responsive platform that delivers personalized, real-time treatment at the seizure source. This platform can drive a better standard of care for patients living with drug-resistant epilepsy and has the potential to offer a more personalized solution and improved outcomes to the large population of patients suffering from other brain disorders.
NEUROPACE, INC. · 8-K · Filed 2026-11-12